Skip to Main Content

What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?

We delve into all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Wall Street Journal reporter John Carreyrou calls in to talk “Bad Blood,” his forthcoming book about how Theranos rose to a $9 billion valuation and then became a cautionary tale for tech and turtlenecks alike. Then we talk about the courtroom drama that awaits Valeant Pharmaceuticals (or whatever it’s going to be called) and explore how biotech’s latest boom cycle creates risk for mom-and-pop investors. Also there’s a lightening round, which, in retrospect, was perhaps ill-advised.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!